Journals / Klinik Psikiyatri Dergisi / 2020 / Cilt: 23 - Sayı: 4

Clinical ımprovement with long-acting aripiprazole in a patient with delusional disorder with hyperprolactinemia: a case report

Hiperprolaktinemi saptanan sanrısal bozukluk tanılı bir hastada uzun etkili aripiprazol ile klinik düzelme: Olgu sunumu

Pages
518–521
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In addition, we think that the use of depot drugs in patients resistant to oral therapy will increase and its use by physicians will become widespread

📌 3 Key Takeaways

🎯
Objective & Hypothesis:DSM-5 named the disorder with one or more systematic, invariant delusions as ‘Delusional Disorder’.
📊
Key Findings & Data:Patients with a diagnosis of delusional disorder have poor internal symptoms and therefore do not consult a doctor themselves, so they are very resistant to drug treatment.
💡
Conclusion & Impact:In addition, we think that the use of depot drugs in patients resistant to oral therapy will increase and its use by physicians will become widespread
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

DSM-5 named the disorder with one or more systematic, invariant delusions as ‘Delusional Disorder’. Patients with a diagnosis of delusional disorder have poor internal symptoms and therefore do not consult a doctor themselves, so they are very resistant to drug treatment. In this article, we will discuss the etiology of prolactin ele-vation in a patient with delusional disorder diagnosed with hyperprolactinemia during antipsychotic treatment. In patients with psychiatric diagnosis, stubbornness of what we consider to be a drug side effect should suggest that an underlying organic cause may exist, and a detailed neuropsychiatric evaluation should be performed. In addition, we think that the use of depot drugs in patients resistant to oral therapy will increase and its use by physicians will become widespread

Özet

DSM-5 bir ya da daha fazla sistematik, değişmez nitelikte sanrıların olduğu bozukluğu ‘Sanrısal Bozukluk’ olarak adlandırmıştır. Sanrısal bozukluk tanılı hastaların iç görüleri zayıf olduğundan doktora kendileri başvurmazlar bu sebeple de ilaç tedavisine karşı oldukça dirençlidirler. Bu yazıda antipsikotik tedavi sürecinde hiperprolaktinemi tespit edilen sanrısal bozukluk tanılı bir hastada, prolak-tin yüksekliğinin etiyolojisini açıklamaya çalışırken yapılan ileri tetkikler ile hipofiz adenomu saptanmasından ayrıca hastada uygun endokrinolojik yaklaşım ve uzun etkili aripiprazol depo kullanımıyla birlikte görülen klinik iyileşmeden bahsedeceğiz. Psikiyatrik tanılı hastalarda özellikle ilaç yan etkisi olarak düşündüğümüz durumların inatçı seyretmesi, altta yatan organik bir nedenin bulunabileceğini akla getirmeli, ayrıntılı nöropsikiyatrik değerlendirme mutlaka yapılmalıdır. Ayrıca günümüzde oral tedaviye dirençli olgularda depo ilaçların önemi giderek arttığından hekimler tarafından kullanımının yaygınlaşacağını düşünmekteyiz.

🔖

Cite This Article

YILDIZ, S., UĞUR, K. (2020). Clinical ımprovement with long-acting aripiprazole in a patient with delusional disorder with hyperprolactinemia: a case report. Klinik Psikiyatri Dergisi, Cilt: 23 - Sayı: 4, 518–521. https://ajindex.com/articles/208997

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Winokur G. Delusional Disorder (Paranoia). ComphernsivePsychiatry 1977; 18: 511-521. 2. Jolene RB, Pharm D, Sally KG. Pharmacotherapy 2009; 29: 64-73. 3. Windgassen KW, Wesselmann U, Mönking H. Galactorrhea and hyperprolactinemia in schizophrenicpatients on neuroleptics: frequencyandetiology. Neuropsychobiology 1996; 33:142-146. 4. Kane JM, Meltzer HY, Carson WH, McQuade RD, Marcus RN, Sanches R, Aripiprazole Study Group. Aripiprazole for treatment-resistant schizophrenia: Results of a multicenter, randomized, double-blind, comparison study versus perphenazine. Journal of Clinical Psychiatry 2007; 68: 213–223. 5. Saitis M, Papazisis G, Katsigiannopoulos K, Kouvelas D. Aripiprazole resolves amisulpride and ziprasidone induced hyperprolactinemia. Psychiatry Clin Neurosci 2008; 62: 624. 6. Haddad PM, Sharma SG. Adverseeffects of atypical antipsychotics differential risk and clinical implications. CNS Drugs 2007; 21:911–936. 7. Bulut SD, Bulut S, Alataş E. Antipsikotiklere bağlı hiperprolaktinemi. Psikiyatride Güncel Yaklaşımlar 2015; 7(2), 109-124. 8. Grunder G, Wetzel H, Schlosser R, Anghelescu I, Hillert A, Lange K,Hiemke C,Benkert O. Neuroendocrine response to antipsychotics: effects of drug type and gender. Biol Psychiatry 1999; 45: 89-97. 9. Marder SR, Essock SM, Miller AL, Buchanan RW, Casey DE, Davis JM, Kane JM, Lieberman JA, Schooler NR, Covell N, Stroup S, Weissman EM, Wirshing DA, Hall CS, Pogach L, Sunyer X, Bigger JT, Friedman A, Kleinberg D, Yevich SJ, Davis B, Shon S. Physical health monitoring of patients with schizophrenia. Am J Psychiatry 2004; 161:1334–1349. 10. Shim JC, Shin JG, Kelly DL, Jung DU,Seo YS, Liu KH, Shon JH, Conley RR. Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychot icinduced hyper-prolactinemia: a placebo-controlled trial. Am J Psychiatry 2007; 164:1404–1410. 11. Checkley S. Neuroendocrine effects of psychotropic drugs. Baillieres Best Pract Res Clin Endocrinol Metab 1991; 5:15-33. 12. Yeager A, Shad MU. Aripiprazole for the Management of Antipsychotic-Induced Hyperprolactinemia A Retrospective Case Series. Prim Care Companion CNS Disord. 2020; 30: 22(1).